

# Jordi Bruix

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7097626/jordi-bruix-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

303  
papers

86,771  
citations

107  
h-index

294  
g-index

355  
ext. papers

98,628  
ext. citations

8.1  
avg. IF

8.4  
L-index

#	Paper	IF	Citations
303	HCC-neuroendocrine transition: Tumor plasticity under immunotherapy. <i>Gastroenterología Y Hepatología</i> , <b>2022</b> ,	0.9	
302	Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 428-428	2.2	0
301	ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS498-TPS498	2.2	2
300	First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.. <i>Liver Cancer</i> , <b>2022</b> , 11, 75-84	9.1	4
299	Reply to: "Correspondence on the".. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	
298	Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	1
297	BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	127
296	Reply to: "An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously". <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	1
295	Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , <b>2021</b> , 55, 263-270	3	2
294	Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity. <i>Oncotarget</i> , <b>2021</b> , 12, 440-449	3.3	0
293	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. <i>Gut</i> , <b>2021</b> ,	19.2	21
292	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica</i> , <b>2021</b> , 156, 463.e1-463.e30	1	2
291	Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	11
290	Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 555	9.8	2
289	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , <b>2021</b> , 156, 463.e1-463.e30	0.3	0
288	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , <b>2021</b> , 3, 100260	0.3	11
287	Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1483-1488	13.4	9

286	Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1154-1163	13.4	3
285	Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 655-661	5.3	1
284	Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. <i>Cancer Management and Research</i> , <b>2021</b> , 13, 5523-5533	3.6	1
283	Local and Regional Therapies for Hepatocellular Carcinoma. <i>Hepatology</i> , <b>2021</b> , 73 Suppl 1, 137-149	11.2	25
282	Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
281	Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules $\geq$ cm in cirrhotic patients. <i>European Radiology</i> , <b>2021</b> , 31, 4794-4803	8	3
280	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , <b>2021</b> , 135, 109484	4.7	9
279	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , <b>2021</b> , 27, 1767-1778	4.5	3
278	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2991-3001	2.2	51
277	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 960-974	13.4	49
276	Hepatic epithelioid hemangioendothelioma: An international multicenter study. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1041-1046	3.3	7
275	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , <b>2020</b> , 40, 1467-1476	7.9	8
274	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2020</b> , 17, 557-588	24.2	355
273	Does transient arterial-phase respiratory-motion-related artifact impact on diagnostic performance? An intra-patient comparison of extracellular gadolinium versus gadoxetic acid. <i>European Radiology</i> , <b>2020</b> , 30, 6694-6701	8	3
272	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 86, 101993	14.4	24
271	Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2020</b> , 1866, 165687	6.9	5
270	Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , <b>2020</b> , 72, 1267-1282	11.2	15
269	Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models. <i>Cancers</i> , <b>2020</b> , 12,	6.6	9

268	Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 478-478	2.2	62
267	Reply to: "The reported Qlear cut time association between interferon-free treatment and HCCOs anything but clear cut". <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1036-1037	13.4	1
266	Letter: are sorafenib-related adverse events associated with prolonged survival? AuthorsReply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 192	6.1	
265	Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , <b>2020</b> , 24, 719-737	4.6	14
264	Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials. <i>Liver International</i> , <b>2020</b> , 40, 2476-2488	7.9	1
263	Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. <i>European Radiology</i> , <b>2020</b> , 30, 186-194	8	11
262	Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 482-491	6.1	30
261	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 874-884	13.4	44
260	Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response". <i>Journal of Hepatology</i> , <b>2019</b> , 71, 447-448	13.4	44
259	Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules $\geq$ 1 cm in cirrhosis. <i>Liver International</i> , <b>2019</b> , 39, 1281-1291	7.9	9
258	Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , <b>2019</b> , 156, 1731-1741	13.3	110
257	Controversies in the management of hepatocellular carcinoma. <i>JHEP Reports</i> , <b>2019</b> , 1, 17-29	10.3	26
256	Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <i>Gut</i> , <b>2019</b> , 68, 1065-1075	19.2	100
255	Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues. <i>Cancer Research</i> , <b>2019</b> , 79, 5167-5180	10.1	19
254	Insights into the success and failure of systemic therapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2019</b> , 16, 617-630	24.2	82
253	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 3176-3184	8.7	43
252	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , <b>2018</b> , 19, 682-693	21.7	216
251	Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. <i>European Journal of Radiology</i> , <b>2018</b> , 101, 72-81	4.7	140

250	Lenvatinib: can a non-inferiority trial change clinical practice?. <i>Lancet, The</i> , <b>2018</b> , 391, 1123-1124	40	10
249	Hepatocellular carcinoma. <i>Lancet, The</i> , <b>2018</b> , 391, 1301-1314	40	2402
248	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 353-358	13.4	200
247	Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma". <i>Journal of Hepatology</i> , <b>2018</b> , 68, 620-621	13.4	
246	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , <b>2018</b> , 67, 612-622	11.2	44
245	Liver Metastases From Gastric Adenocarcinoma Mimicking Multinodular Hepatocellular Carcinoma. <i>Hepatology</i> , <b>2018</b> , 68, 2042-2044	11.2	1
244	Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 412-412	2.2	36
243	Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2018</b> , 32, 2345-2354	5.2	14
242	Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). <i>Liver Transplantation</i> , <b>2018</b> , 24, 369-379	4.5	32
241	Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 16701-16717	3.3	32
240	Locoregional versus systemic therapy - robust positive data remain elusive. <i>Nature Reviews Clinical Oncology</i> , <b>2018</b> , 15, 537-538	19.4	3
239	The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma. <i>Liver International</i> , <b>2017</b> , 37 Suppl 1, 136-139	7.9	25
238	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , <b>2017</b> , 389, 56-66	40	1888
237	Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. <i>European Journal of Pharmaceutical Sciences</i> , <b>2017</b> , 109S, S149-S153	5.1	16
236	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica</i> , <b>2017</b> , 149, 61-71	1	13
235	Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?. <i>Seminars in Liver Disease</i> , <b>2017</b> , 37, 109-118	7.3	59
234	Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2017</b> , 14, 203-217	24.2	196
233	Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. <i>Medicina Clínica (English Edition)</i> , <b>2017</b> , 149, 61-71	0.3	1

232	Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication. <i>Virus Research</i> , <b>2017</b> , 240, 35-46	6.4	2
231	Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 999-1008	13.4	321
230	Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4078-4078	2.2	9
229	Weak correlation of overall survival and time to progression in advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 233-233	2.2	7
228	Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. <i>Oncotarget</i> , <b>2017</b> , 8, 90185-90196	3.3	5
227	Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 2448-2452	5.6	9
226	Regorafenib and the RESORCE trial: a new second-line option for hepatocellular carcinoma patients. <i>Hepatic Oncology</i> , <b>2016</b> , 3, 187-189	4	4
225	Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing". <i>Journal of Hepatology</i> , <b>2016</b> , 65, 864-865	13.4	6
224	Reply. <i>Hepatology</i> , <b>2016</b> , 63, 1054-5	11.2	2
223	Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , <b>2016</b> , 34, 597-602	3.2	51
222	Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1090-1098	13.4	407
221	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , <b>2016</b> , 150, 835-53	13.3	1012
220	Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 197-197	2.2	3
219	Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF- $\beta$ pathway. <i>Oncotarget</i> , <b>2016</b> , 7, 71309-71329	3.3	23
218	Akt-mediated foxo1 inhibition is required for liver regeneration. <i>Hepatology</i> , <b>2016</b> , 63, 1660-74	11.2	34
217	Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. <i>Hepatology</i> , <b>2016</b> , 63, 839-49	11.2	74
216	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 719-726	13.4	709
215	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 1923-36	4	12

214	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , <b>2016</b> , 146, 511.e1-511.e22	0.3	1
213	Biopsy for liver cancer: how to balance research needs with evidence-based clinical practice. <i>Hepatology</i> , <b>2015</b> , 61, 433-6	11.2	28
212	Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience. <i>Hpb</i> , <b>2015</b> , 17, 387-93 <sup>8</sup>	3.8	33
211	Systemic Treatment: Expecting Further Success. <i>Digestive Diseases</i> , <b>2015</b> , 33, 590-7	3.2	1
210	Liver cancer: Approaching a personalized care. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S144-56	13.4	175
209	Intermediate-stage HCC--upfront resection can be feasible. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12,	19.4	6
208	Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. <i>Radiology</i> , <b>2015</b> , 275, 698-707	20.5	99
207	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1344-54	21.7	553
206	Reply to: Poor contrast enhanced ultrasonography! There is no limit to its decline in the diagnosis of hepatocellular carcinoma on cirrhosis! <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1453-4	13.4	
205	Reply: Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery. <i>Nature Reviews Clinical Oncology</i> , <b>2015</b> , 12, 10	19.4	14
204	Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules . <i>Journal of Hepatology</i> , <b>2015</b> , 62, 150-5	13.4	28
203	Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. <i>Hepatology</i> , <b>2015</b> , 61, 526-36	11.2	207
202	LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. <i>Hepatology</i> , <b>2015</b> , 61, 1056-65	11.2	333
201	Reply: To PMID 25212123. <i>Hepatology</i> , <b>2015</b> , 62, 978-9	11.2	
200	A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations? An Observational Study of the HCC East-West Study Group. <i>Annals of Surgery</i> , <b>2015</b> , 262, e30	7.8	18
199	Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma. <i>Annals of Surgery</i> , <b>2015</b> , 261, e105	7.8	8
198	Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 2509-23	3.3	55
197	SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 559-66	2.2	374

196	Authors' response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al. <i>Gut</i> , <b>2015</b> , 64, 522	19.2	1
195	The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma. <i>Hepatology International</i> , <b>2014</b> , 8, 4-6	8.8	1
194	Liver Transplantation for Hepatocellular Carcinoma in HCV-Infected Patients <b>2014</b> , 77-93		
193	Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3451-60	5.9	15
192	Systemic treatment. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2014</b> , 28, 921-35	2.5	9
191	Treatment of intermediate-stage hepatocellular carcinoma. <i>Nature Reviews Clinical Oncology</i> , <b>2014</b> , 11, 525-35	19.4	315
190	: a journal for all stakeholders in liver cancer management. <i>Hepatic Oncology</i> , <b>2014</b> , 1, 1	4	
189	FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive?. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 164-5	13.4	3
188	Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 318-24	13.4	172
187	Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. <i>Hepatic Oncology</i> , <b>2014</b> , 1, 181-188	4	14
186	Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. <i>Seminars in Liver Disease</i> , <b>2014</b> , 34, 444-55	7.3	83
185	Treatment of hepatocellular carcinoma. <i>Digestive Diseases</i> , <b>2014</b> , 32, 554-63	3.2	29
184	Hepatocellular carcinoma: paving the road for further developments. <i>Seminars in Liver Disease</i> , <b>2014</b> , 34, 361	7.3	1
183	Hepatocellular carcinoma: clinical frontiers and perspectives. <i>Gut</i> , <b>2014</b> , 63, 844-55	19.2	953
182	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4006-4006	2.2	28
181	RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS4156-TPS4156	2.2	
180	A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma. <i>Journal of Molecular Medicine</i> , <b>2013</b> , 91, 939-50	5.5	26
179	Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. <i>Hepatology</i> , <b>2013</b> , 58, 2023-31	11.2	162



178	Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3412-9	7.5	178
177	Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1271-7	13.4	60
176	The size of the problem: clinical algorithms. <i>Digestive Diseases</i> , <b>2013</b> , 31, 95-103	3.2	5
175	Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 452-9	13.4	7
174	Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3509-16	2.2	468
173	Treatment of hepatocellular carcinoma with radioembolization: gathering assumptions for trial design. <i>Journal of Vascular and Interventional Radiology</i> , <b>2013</b> , 24, 1197-9	2.4	2
172	Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. <i>Gastroenterology</i> , <b>2013</b> , 144, 829-40	13.3	317
171	Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4290	12.9	11
170	Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4159-TPS4159	2.2	5
169	Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS4163-TPS4163	2.2	1
168	Management of HCC. <i>Journal of Hepatology</i> , <b>2012</b> , 56 Suppl 1, S75-87	13.4	438
167	Hepatocellular carcinoma. <i>Lancet, The</i> , <b>2012</b> , 379, 1245-55	40	3423
166	Hepatocellular carcinoma [AuthorsReply]. <i>Lancet, The</i> , <b>2012</b> , 380, 470-471	40	26
165	Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4997-5007	12.9	195
164	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 103-8	13.4	114
163	Chemoembolization for intermediate HCC: is there proof of survival benefit?. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 984-6	13.4	89
162	EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 908-43	13.4	4465
161	Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1080-1088	13.4	88

160	Non-invasive diagnosis of hepatocellular carcinoma $\geq$ 2 cm in cirrhosis. Diagnostic accuracy assessing fat, capsule and signal intensity at dynamic MRI. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1317-23	13.4	135
159	Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 1330-5	13.4	354
158	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 821-9	13.4	589
157	Biomarkers for early diagnosis of hepatocellular carcinoma. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 750-1	21.7	86
156	Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2290-300	12.9	426
155	Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. <i>Gut</i> , <b>2012</b> , 61, 1481-7	19.2	121
154	Screening for liver cancer: the rush to judgment. <i>Annals of Internal Medicine</i> , <b>2012</b> , 157, 300-1; author reply 301-2	8	2
153	Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA154-LBA154	2.2	55
152	Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. <i>Annals of Saudi Medicine</i> , <b>2012</b> , 32, 174-99	1.6	19
151	Diagnosis of early hepatocellular carcinoma: ideal goal, but not yet there. <i>Gastroenterology</i> , <b>2011</b> , 140, 358-60	13.3	2
150	Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. <i>Gastroenterology</i> , <b>2011</b> , 140, 1501-12.e2	13.3	307
149	MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. <i>Gastroenterology</i> , <b>2011</b> , 140, 1618-28.e16	13.3	181
148	Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. <i>Gastroenterology</i> , <b>2011</b> , 140, 1990-9	13.3	95
147	The search for an effective partner for sorafenib: the failure of doxorubicin. <i>Gastroenterology</i> , <b>2011</b> , 140, 1687-8	13.3	1
146	FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC program. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 227-35	13.4	16
145	Gene-expression signature of vascular invasion in hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1325-31	13.4	108
144	Management of hepatocellular carcinoma: an update. <i>Hepatology</i> , <b>2011</b> , 53, 1020-2	11.2	6091
143	Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. <i>Hepatology</i> , <b>2011</b> , 54, 2238-44	11.2	84

142	Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. <i>Journal of Oncology Practice</i> , <b>2011</b> , 7, 155-60	3.1	7
141	Two decades of advances in hepatocellular carcinoma research. <i>Seminars in Liver Disease</i> , <b>2010</b> , 30, 1-2	7.3	18
140	Current strategy for staging and treatment: the BCLC update and future prospects. <i>Seminars in Liver Disease</i> , <b>2010</b> , 30, 61-74	7.3	77 <sup>o</sup>
139	Treatment of early hepatocellular carcinoma: Towards personalized therapy. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42 Suppl 3, S242-8	3.3	27
138	Failure of interferon to prevent disease progression and liver cancer in hepatitis C virus infection: proof of absence or absence of proof?. <i>Gastroenterology</i> , <b>2010</b> , 138, 777-9	13.3	1
137	MicroRNA analysis for outcome prediction in hepatitis B virus-related liver cancer. <i>Gastroenterology</i> , <b>2010</b> , 138, 1624-6; discussion 1626-7	13.3	1
136	Ablation for hepatocellular carcinoma: Is there need to have a winning technique?. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 310-2	13.4	15
135	IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 550-9	13.4	19 <sup>o</sup>
134	A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2010</b> , 10, 209	4.8	138
133	Hepatocellular carcinoma (HCC): a global perspective. <i>Journal of Clinical Gastroenterology</i> , <b>2010</b> , 44, 239-45	3.5	218
132	Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2010</b> , 22, 1239-44	2.2	16
131	Medical treatments: in association or alone, their roles and their future perspectives: the Western experience. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , <b>2010</b> , 17, 420-1	2.8	1
130	A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. <i>Hepatology</i> , <b>2010</b> , 51, 1274-83	11.2	292
129	Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. <i>Hepatology</i> , <b>2010</b> , 51, 2020-9	11.2	209
128	Reply:. <i>Hepatology</i> , <b>2010</b> , 52, 1516-1517	11.2	
127	East meets the West--portal pressure predicts outcome of surgical resection for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , <b>2009</b> , 6, 14-5		12
126	Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. <i>Hepatology</i> , <b>2009</b> , 50, 791-8	11.2	207
125	Reply:. <i>Hepatology</i> , <b>2009</b> , 50, 1316-1317	11.2	

124	The need for novel and interesting data in liver cancer research. <i>Hepatology</i> , <b>2009</b> , 50, 1690-1	11.2	0
123	Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. <i>Cancer</i> , <b>2009</b> , 115, 616-23	6.4	359
122	New drugs for the treatment of hepatocellular carcinoma. <i>Liver International</i> , <b>2009</b> , 29 Suppl 1, 148-58	7.9	19
121	Angiogenesis in liver disease. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 604-20	13.4	438
120	Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 725-33	13.4	182
119	Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. <i>Gastroenterology</i> , <b>2009</b> , 136, 1618-28.e2	13.3	197
118	Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. <i>Gastroenterology</i> , <b>2009</b> , 137, 26-9	13.3	77
117	To expand or not to expand the criteria for hepatocellular carcinoma transplantation: is downstaging the answer?. <i>Gastroenterology</i> , <b>2009</b> , 137, 375-6; discussion 377	13.3	2
116	Sorafenib for hepatocellular carcinoma: global validation. <i>Gastroenterology</i> , <b>2009</b> , 137, 1171-3	13.3	4
115	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 35-43	21.7	1490
114	Sunitinib and the benefits of a negative study. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 743-4	21.7	8
113	Major achievements in hepatocellular carcinoma. <i>Lancet, The</i> , <b>2009</b> , 373, 614-6	40	244
112	Sorafenib in advanced hepatocellular carcinoma. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 378-90	59.2	9089
111	Pivotal role of mTOR signaling in hepatocellular carcinoma. <i>Gastroenterology</i> , <b>2008</b> , 135, 1972-83, 1983.e1-11	13.1	563
110	Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. <i>Cancer Research</i> , <b>2008</b> , 68, 6779-88	10.1	463
109	Novel advancements in the management of hepatocellular carcinoma in 2008. <i>Journal of Hepatology</i> , <b>2008</b> , 48 Suppl 1, S20-37	13.4	635
108	Design and endpoints of clinical trials in hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 698-711	9.7	1360
107	Gene expression in fixed tissues and outcome in hepatocellular carcinoma. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1995-2004	59.2	979

106	Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. <i>Hepatology</i> , <b>2008</b> , 47, 97-104	11.2	718
105	Reply: <i>Hepatology</i> , <b>2008</b> , 47, 2146-2147	11.2	8
104	Molecular targeted therapies in hepatocellular carcinoma. <i>Hepatology</i> , <b>2008</b> , 48, 1312-27	11.2	801
103	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. <i>Hepatology</i> , <b>2007</b> , 45, 938-47	11.2	557
102	Transarterial chemoembolization for patients with hepatocellular carcinoma. <i>Hepatology Research</i> , <b>2007</b> , 37 Suppl 2, S230-7	5.1	12
101	Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. <i>Journal of Hepatology</i> , <b>2007</b> , 46, 645-54	13.4	67
100	Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. <i>Journal of Hepatology</i> , <b>2007</b> , 46, 474-81	13.4	734
99	Reply: Chemoembolization with drug eluting beads in HCC. <i>Journal of Hepatology</i> , <b>2007</b> , 47, 159	13.4	1
98	Treatment of hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2006</b> , 60, 89-98	7	123
97	Hepatocellular carcinoma in the setting of liver transplantation. <i>Liver Transplantation</i> , <b>2006</b> , 12, 1028-36	4.5	24
96	Expanded criteria for hepatocellular carcinoma through down-staging prior to liver transplantation: not yet there. <i>Seminars in Liver Disease</i> , <b>2006</b> , 26, 248-53	7.3	26
95	Distinct cellular responses differentiating alcohol- and hepatitis C virus-induced liver cirrhosis. <i>Virology Journal</i> , <b>2006</b> , 3, 98	6.1	27
94	A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. <i>Gastroenterology</i> , <b>2006</b> , 131, 1758-67	13.3	319
93	Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 8-10	13.4	12
92	New aspects of diagnosis and therapy of hepatocellular carcinoma. <i>Oncogene</i> , <b>2006</b> , 25, 3848-56	9.2	125
91	Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?. <i>European Radiology</i> , <b>2006</b> , 16, 2454-62	8	84
90	Applicability of adult-to-adult living donor liver transplantation. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 104-9	13.4	17
89	Diagnosis of Small HCC. <i>Gastroenterology</i> , <b>2005</b> , 129, 1364	13.3	24

88	Liver transplantation in hepatocellular carcinoma. <i>Transplant International</i> , <b>2005</b> , 18, 278-82	3	22
87	Ecografía con contraste de segunda generación (SonoVue®) en la valoración del tratamiento percutáneo del carcinoma hepatocelular. Comparación con la TC multifásica. <i>Radiología</i> , <b>2005</b> , 47, 79-85	0.6	1
86	Management of hepatocellular carcinoma. <i>Hepatology</i> , <b>2005</b> , 42, 1208-36	11.2	4778
85	Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography. <i>Digestive Diseases and Sciences</i> , <b>2005</b> , 50, 533-7	4	16
84	Prognostic prediction in patients with hepatocellular carcinoma. <i>Seminars in Liver Disease</i> , <b>2005</b> , 25, 171-80	7.9	71
83	Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. <i>Radiology</i> , <b>2004</b> , 230, 300-1; author reply 301-2	20.5	18
82	Focus on hepatocellular carcinoma. <i>Cancer Cell</i> , <b>2004</b> , 5, 215-9	24.3	472
81	Prognostic prediction in HCC: Did anybody expect it to be easy?. <i>Hepatology</i> , <b>2004</b> , 39, 551-552	11.2	13
80	Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. <i>Hepatology</i> , <b>2004</b> , 40, 1047-52	11.2	130
79	Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. <i>Hepatology</i> , <b>2004</b> , 40, 1352-60	11.2	340
78	The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. <i>Liver Transplantation</i> , <b>2004</b> , 10, S115-20	4.5	513
77	High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. <i>Liver Transplantation</i> , <b>2004</b> , 10, 1294-300	4.5	229
76	Selection of candidates with HCC for transplantation in the MELD era. <i>Liver Transplantation</i> , <b>2004</b> , 10, S4-9	4.5	31
75	Preoperative evaluation of biliary anatomy in adult live liver donors with volumetric mangafodipir trisodium enhanced magnetic resonance cholangiography. <i>Liver Transplantation</i> , <b>2004</b> , 10, 1391-7	4.5	33
74	Chemoembolization for hepatocellular carcinoma. <i>Gastroenterology</i> , <b>2004</b> , 127, S179-88	13.3	434
73	Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 2150-7	12.9	22
72	Abdominal drainage after liver resection for hepatocellular carcinoma in cirrhotic patients: a randomized controlled study. <i>Hepato-Gastroenterology</i> , <b>2004</b> , 51, 536-40		23
71	Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. <i>Hepatology</i> , <b>2003</b> , 37, 429-42	11.2	2207

70	Liver transplantation for hepatocellular carcinoma: Foucault pendulum versus evidence-based decision. <i>Liver Transplantation</i> , <b>2003</b> , 9, 700-2	4.5	79
69	MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation. <i>Hepatology</i> , <b>2003</b> , 38, 1034-1042	11.2	331
68	Contrast-enhanced power Doppler sonography and helical computed tomography for assessment of vascularity of small hepatocellular carcinomas before and after percutaneous ablation. <i>Journal of Clinical Ultrasound</i> , <b>2003</b> , 31, 119-28	1	27
67	Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. <i>Hepatology</i> , <b>2003</b> , 38, 1458-67	11.2	67
66	Treatment strategies for hepatocellular carcinoma in cirrhosis. <i>Journal of Gastrointestinal Surgery</i> , <b>2003</b> , 7, 401-11	3.3	15
65	p27(Kip1) is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2003</b> , 38, 591-7	13.4	37
64	Hepatitis B virus and hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2003</b> , 39 Suppl 1, S59-63	13.4	79
63	Hepatocellular carcinoma. <i>Lancet, The</i> , <b>2003</b> , 362, 1907-17	40	3580
62	Treatment of hepatocellular carcinoma: is there an optimal strategy?. <i>Cancer Treatment Reviews</i> , <b>2003</b> , 29, 99-104	14.4	58
61	MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. <i>Hepatology</i> , <b>2003</b> , 38, 1034-42	11.2	126
60	Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. <i>Cancer Research</i> , <b>2003</b> , 63, 859-64	10.1	110
59	Expected developments in hepatology. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2002</b> , 16, 957-70	2.5	5
58	Prognostic prediction and treatment strategy in hepatocellular carcinoma. <i>Hepatology</i> , <b>2002</b> , 35, 519-24	11.2	843
57	Interferon for the prevention of hepatocellular carcinoma. <i>Perspectives in Medical Virology</i> , <b>2002</b> , 6, 151-159		
56	Prognostic assessment and evaluation of the benefits of treatment. <i>Journal of Clinical Gastroenterology</i> , <b>2002</b> , 35, S138-42	3	26
55	Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. <i>Lancet, The</i> , <b>2002</b> , 359, 1734-9	40	2679
54	Prognosis of hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , <b>2002</b> , 49, 7-11		22
53	Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. <i>Hepatology</i> , <b>2001</b> , 33, 1124-9	11.2	595

52	High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. <i>Hepatology</i> , <b>2001</b> , 34, 158-67	11.2	38
51	Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. <i>Journal of Hepatology</i> , <b>2001</b> , 35, 421-30	13.4	355 <sup>8</sup>
50	Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. <i>Hepatology</i> , <b>2001</b> , 33, 1073-9	11.2	200
49	Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. <i>Hepatology</i> , <b>2000</b> , 31, 54-8	11.2	192
48	Early diagnosis and treatment of hepatocellular carcinoma. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2000</b> , 14, 991-1008	2.5	37
47	Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. <i>Hepatology</i> , <b>2000</b> , 32, 679-80	11.2	107
46	Nonsurgical treatment of hepatocellular carcinoma. <i>Liver Transplantation</i> , <b>2000</b> , 6, S11-5	4.5	19
45	The current status of liver transplantation for primary hepatic malignancy. <i>Clinics in Liver Disease</i> , <b>2000</b> , 4, 591-605	4.6	21
44	Hepatocellular carcinoma and the art of prognostication. <i>Journal of Hepatology</i> , <b>2000</b> , 33, 1006-8	13.4	16
43	Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients presenting with spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , <b>2000</b> , 33, 423-9	13.4	19
42	Prognosis of hepatocellular carcinoma: the BCLC staging classification. <i>Seminars in Liver Disease</i> , <b>1999</b> , 19, 329-38	7.3	2729
41	Locoregional treatments for hepatocellular carcinoma. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>1999</b> , 13, 611-22	2.5	13
40	Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. <i>Hepatology</i> , <b>1999</b> , 29, 62-7	11.2	864
39	Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. <i>Hepatology</i> , <b>1999</b> , 30, 1434-40	11.2	1594
38	Infection with a novel human DNA virus (TTV) has no pathogenic significance in patients with liver diseases. <i>Journal of Hepatology</i> , <b>1999</b> , 30, 1028-34	13.4	59
37	Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. <i>Hepatology</i> , <b>1998</b> , 27, 1572-7	11.2	302
36	Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. <i>Hepatology</i> , <b>1998</b> , 27, 1578-83	11.2	403
35	Tumor necrosis factor primes hepatocytes for DNA replication in the rat. <i>Hepatology</i> , <b>1998</b> , 28, 1226-34	11.2	238



34	Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. <i>Journal of Hepatology</i> , <b>1998</b> , 29, 173-83	13.4	128
33	Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>1997</b> , 27, 959-65	13.4	107
32	Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. <i>Annals of Surgery</i> , <b>1996</b> , 223, 297-302	7.8	172
31	Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. <i>Gastroenterology</i> , <b>1995</b> , 109, 917-22	13.3	160
30	Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. <i>Journal of Hepatology</i> , <b>1995</b> , 22, 410-5	13.4	80
29	Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. <i>Journal of Hepatology</i> , <b>1995</b> , 22, 616-22	13.4	27
28	c-met mRNA overexpression in human hepatocellular carcinoma. <i>Hepatology</i> , <b>1994</b> , 19, 88-91	11.2	104
27	Phase II study of transarterial embolization in european patients with hepatocellular carcinoma: Need for controlled trials. <i>Hepatology</i> , <b>1994</b> , 20, 643-650	11.2	77
26	nm23-H1 expression and disease recurrence after surgical resection of small hepatocellular carcinoma. <i>Gastroenterology</i> , <b>1994</b> , 107, 486-91	13.3	26
25	c-met mRNA overexpression in human hepatocellular carcinoma <b>1994</b> , 19, 88		5
24	Phase II study of transarterial embolization in european patients with hepatocellular carcinoma: Need for controlled trials <b>1994</b> , 20, 643		2
23	Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment?. <i>Journal of Hepatology</i> , <b>1993</b> , 17, 187-91	13.4	55
22	Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection. <i>Hepatology</i> , <b>1993</b> , 18, 1121-1126	11.2	246
21	Surgical resection and survival in Western patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>1992</b> , 15, 350-5	13.4	24
20	Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. <i>Hepatology</i> , <b>1992</b> , 16, 353-7	11.2	233
19	Diarrhea as a presenting symptom of hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , <b>1990</b> , 35, 681-5	4	15
18	Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. <i>Hepatology</i> , <b>1990</b> , 12, 753-60	11.2	202
17	Natural history of hepatocellular carcinoma in Spain. Five year experience in 249 cases. <i>Journal of Hepatology</i> , <b>1990</b> , 10, 311-7	13.4	111

16	Diagnostic accuracy of fine-needle aspiration biopsy in patients with hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , <b>1989</b> , 34, 1765-9	4	44
15	Beta-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. <i>Hepatology</i> , <b>1989</b> , 10, 269-72	11.2	18
14	Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. <i>Lancet, The</i> , <b>1989</b> , 2, 1004-6	40	571
13	Endoscopic measurement of variceal pressure in cirrhosis: Correlation with portal pressure and variceal hemorrhage. <i>Gastroenterology</i> , <b>1989</b> , 96, 873-880	13.3	71
12	Endoscopic Measurement of Variceal Pressure in Cirrhosis: Correlation With Portal Pressure and Variceal Hemorrhage. <i>Gastroenterology</i> , <b>1989</b> , 96, 873-880	13.3	125
11	Esophageal dysfunction in primary biliary cirrhosis. <i>Journal of Hepatology</i> , <b>1988</b> , 7, 362-7	13.4	8
10	Effects of metoclopramide and domperidone on azygos venous blood flow in patients with cirrhosis and portal hypertension. <i>Hepatology</i> , <b>1986</b> , 6, 1244-7	11.2	35
9	Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. <i>Hepatology</i> , <b>1985</b> , 5, 245-50	11.2	105
8	Measurement of azygos venous blood flow in the evaluation of portal hypertension in patients with cirrhosis. Clinical and haemodynamic correlations in 100 patients. <i>Journal of Hepatology</i> , <b>1985</b> , 1, 125-39	13.4	160
7	Comparison of intravenous somatostatin and vasopressin infusions in treatment of acute variceal hemorrhage. <i>Hepatology</i> , <b>1984</b> , 4, 442-6	11.2	214
6	Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. <i>Hepatology</i> , <b>1984</b> , 4, 1200-5	11.2	260
5	Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. <i>Hepatology</i> , <b>1982</b> , 2, 757-62	11.2	196
4	Transarterial Embolization for Patients with Hepatocellular Carcinoma	139-150	
3	Tumors of the Liver	773-785	
2	Malignant Tumours	1437-1463	1
1	Management of Hepatocellular Cancer	740-754	